TherapeutAix is a life sciences consultancy operating globally out of Aachen (Aix-la-Chapelle), Germany. It combines hands-on expertise with an integrated R&D network to add value to projects. TherapeutAix is working with pharma and biotech companies, academic institutions, and incubators to help bring molecules with promise to life.
The TherapeutAix directors have a successful track record in the cardiovascular, inflammation, immunology (including immune-oncology), fibrotic, respiratory, neuroscience, pain, tissue repair and urology areas. They have individually worked for major companies such as AstraZeneca, Merck, Pfizer, Glaxo, and Bayer, and successfully worked for four years together as the Innovative Medicines Unit for Grünenthal.
Professional services include due diligence of new opportunities and review of existing projects; rapid, cost-effective assessment of project data and plans at all stages of drug discovery; strategic planning to maximise the impact of positive scientific data, and collaborative delivery of decision-making data and information via an R&D network. Uniquely, this allows TherapeutAix to co-ordinate a “wet due diligence” process and to utilize a workshop-based approach to build a cohesive strategy for each project.